Reported 23 days ago
In a recent discussion on CNBC, Jim Cramer expressed strong disapproval of Johnson & Johnson's decision to spin off its consumer health division, Kenvue, labeling it ill-advised and suggesting that the action removed valuable brands from the company's portfolio. He voiced concerns about the potential negative impacts on the company's growth pipeline, emphasizing that while the move might have been aimed at achieving higher market multiples, it could lead to significant long-term challenges.
Source: YAHOO